Hangzhou Just Biotherapeutics (Just China), a Hangzhou, China-based developer of global antibody and recombinant protein bio-therapeutics, raised $57M in Series B financing.
The round was led by Temasek, followed by existing investors Lilly Asia Ventures (LAV) and ARCH Venture Partners and new investors Taikang, Hangzhou Economic & Technological Development Area (HEDA), Bank of China (BOC) and Bank of Hangzhou.
The company intends to use the funds to further advance biologics development and clinical trials.
Led by Dr. Yining Zhao, Co-founder and CEO, Just China leverages knowledge in the fields of protein, process and manufacturing sciences to solve the scientific and technical hurdles that block access to life changing protein therapeutics, from the design of therapeutic molecules to the design of the manufacturing plants used to produce them.
Just China was founded in February 2016 as a joint venture with Just Biotherapeutics, Inc. (Just), located in Seattle, Washington, USA. As an affiliate, it will have access to Just’s integrated technology platform, J.DESIGN, and will closely partner with Just to evolve the platform. Applying J.DESIGN technology to molecule, process, product, manufacturing and plant design will enable the company to develop biologics while accelerating the development process and substantially reducing manufacturing cost.
Just has already established clinical development and CMC capabilities with a pipeline consisting of both bionovel and biosimilar products.
Several programs will start to enter clinical stage in 2018.